NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	27/11/2019
Target sample size	525
Countries of recruitment	Japan,Asia except Japan,North America,South America,Europe,Africa
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : Otilimab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Sarilumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	efficacy
Secondary Outcome	safety efficacy

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria
Exclude criteria